Trials / Completed
CompletedNCT01283373
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I, multicenter, open-label, dose-escalation study of DSTP3086S administered as a single agent by intravenous (IV) infusion to patients with metastatic Castration-Resistant Prostate Cancer (CRPC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DSTP3086S | DSTP3086S administered intravenously |
| DRUG | DSTP3086S | Escalating intravenous dose |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2011-01-26
- Last updated
- 2016-10-04
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01283373. Inclusion in this directory is not an endorsement.